Literature DB >> 12787562

TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor.

Steven R Wiley1, Jeffrey A Winkles.   

Abstract

The cytokine tumor necrosis factor-like weak inducer of apoptosis (TWEAK) was initially described as a member of the tumor necrosis factor (TNF) superfamily in 1997. TWEAK is a cell surface-associated type II transmembrane protein, but a smaller, biologically active form can also be shed into the extracellular milieu. There is one receptor currently known to bind TWEAK with physiological affinity, and it is a type I transmembrane protein that is referred to in the literature as either TWEAK receptor (TweakR) or fibroblast growth factor-inducible 14 (Fn14). TweakR/Fn14 is the smallest member of the TNF receptor (TNFR) superfamily described to date, and it appears to signal via recruitment of several different TNFR-associated factors. TWEAK has multiple biological activities, including stimulation of cell growth and angiogenesis, induction of inflammatory cytokines, and under some experimental conditions, stimulation of apoptosis. In this report, we summarize the results from recent studies focused on the TWEAK cytokine. Although these studies have contributed a significant amount of new information, numerous questions still remain regarding the role of TWEAK in both normal physiology and the pathogenesis of human disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12787562     DOI: 10.1016/s1359-6101(03)00019-4

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  89 in total

1.  Evaluation of serum sTWEAK and sCD163 levels in patients with acute and chronic coronary artery disease.

Authors:  Abdulselam Ilter; Cihan Orem; Fulya Balaban Yucesan; Mursel Sahin; Yusuf Hosoglu; Elif Kurumahmutoglu; Serap Ozer Yaman; Asim Orem
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  TWEAK induces liver progenitor cell proliferation.

Authors:  Aniela Jakubowski; Christine Ambrose; Michael Parr; John M Lincecum; Monica Z Wang; Timothy S Zheng; Beth Browning; Jennifer S Michaelson; Manfred Baetscher; Manfred Baestcher; Bruce Wang; D Montgomery Bissell; Linda C Burkly
Journal:  J Clin Invest       Date:  2005-08-18       Impact factor: 14.808

3.  Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis.

Authors:  Marjaneh Razmara; Brendan Hilliard; Azadeh K Ziarani; Ramachandran Murali; Srikanth Yellayi; Mustafa Ghazanfar; Youhai H Chen; Mark L Tykocinski
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 4.  TWEAK as a target for therapy in systemic lupus erythematosus.

Authors:  Rui-Xue Leng; Hai-Feng Pan; Wei-Zi Qin; Chao Wang; Li-Li Chen; Jin-Hui Tao; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

5.  Visual Experience-Dependent Expression of Fn14 Is Required for Retinogeniculate Refinement.

Authors:  Lucas Cheadle; Christopher P Tzeng; Brian T Kalish; David A Harmin; Samuel Rivera; Emi Ling; M Aurel Nagy; Sinisa Hrvatin; Linda Hu; Hume Stroud; Linda C Burkly; Chinfei Chen; Michael E Greenberg
Journal:  Neuron       Date:  2018-07-19       Impact factor: 17.173

6.  Fn14 receptor promotes invasive potential and metastatic capacity of non-small lung adenocarcinoma cells through the up-regulation of integrin α6.

Authors:  J Jandova; C J Mason; S C Pawar; G S Watts
Journal:  Neoplasma       Date:  2015       Impact factor: 2.575

7.  Transient TWEAK overexpression leads to a general salivary epithelial cell proliferation.

Authors:  T Sugito; F Mineshiba; C Zheng; A P Cotrim; C M Goldsmith; B J Baum
Journal:  Oral Dis       Date:  2008-09-29       Impact factor: 3.511

Review 8.  Role of the TWEAK/Fn14 pathway in autoimmune diseases.

Authors:  Wang-Dong Xu; Yi Zhao; Yi Liu
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

Review 9.  TNF superfamily: a growing saga of kidney injury modulators.

Authors:  Maria D Sanchez-Niño; Alberto Benito-Martin; Sara Gonçalves; Ana B Sanz; Alvaro C Ucero; Maria C Izquierdo; Adrian M Ramos; Sergio Berzal; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  Mediators Inflamm       Date:  2010-10-04       Impact factor: 4.711

10.  TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade.

Authors:  A W R van Kuijk; C A Wijbrandts; M Vinkenoog; T S Zheng; K A Reedquist; P P Tak
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.